Treatment for primary central nervous system lymphoma using R-IDARAM and intrathecal chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of R-IDARAM combined with intrathecal immunochemotherapy in patients with primary central nervous system lymphoma (PCNSL). The study aims to assess response rates, progression-free survival, overall survival, and toxicity associated with this treatment approach. Participants will receive systemic and intrathecal chemotherapy, with radiotherapy deferred to a later stage if necessary. The trial is designed to provide insights into the potential benefits of this combined treatment strategy for PCNSL.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).

Exclusion criteria:

* Involved sites other than the brain, meninges, CSF, or the eyes.
* Age less than 18 years or greater than 75 years.
* Inadequate bone marrow capacity (defined as neutrophils\<1.5 ×10\^9/L, platelets \<100 ×10\^9/L, and hemoglobin level\< 8 g/dL).
* Known cause of immunosuppression (ie, HIV type I infection).
* Any previous malignancy.
* Creatinine clearance below 60 mL/min.
* Heart insufficiency (NYHA IIIB or IV).
* Uncontrolled infection.
* Noncompensated active pulmonary or liver disease.
* Previously treated for PCNSL, except by corticosteroids.

Where it's running

• Navy General Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Liren Qian, M.D.
• Email: qlr2007@126.com
• Phone: +861066957676

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rapid CSF ctDNA Test and Treatment Monitoring for Primary CNS Lymphoma

  This study tests whether CSF circulating tumor DNA can quickly diagnose primary CNS lymphoma and monitor response to treatment in adults.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT07851363

• Testing a four-drug regimen (methotrexate, rituximab, sintilimab, pirtobrutinib) versus investigator-selected care for newly diagnosed PCNSL

  This trial will try a combination of methotrexate, rituximab, sintilimab and pirtobrutinib as first treatment for adults with newly diagnosed primary central nervous system lymphoma to see if it increases complete remissions and is safe compared with standard doctor-selected treatments.

  Recruiting at 3 sites Phase 2 Tongji Hospital · Xiamen, Fujian and 3 other locations · NCT07350850

• Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

  In this study, adults with newly diagnosed primary CNS lymphoma try different induction regimens to see which one works best before consolidation therapy.

  Recruiting at 9 sites Phase 2/3 Huashan Hospital · Beijing and 14 other locations · NCT07185373

• Epcoritamab plus ibrutinib for central nervous system lymphoma

  This trial tests whether combining epcoritamab and ibrutinib is safe and tolerable for adults with relapsed or refractory primary or secondary central nervous system lymphoma.

  Recruiting at 8 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07082868

• Tirabrutinib maintenance therapy for patients with primary CNS lymphoma in remission

  This study is testing if taking tirabrutinib every day can help people with primary CNS lymphoma stay in remission longer after their initial treatment.

  Recruiting Phase 2 Kyorin University · Tokyo · NCT06940791

• Glofitamab after obinutuzumab pre-treatment for central nervous system lymphoma

  This trial will test if giving glofitamab after a short obinutuzumab pre-treatment is safe and helpful for adults with primary or secondary central nervous system lymphoma.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06922604

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.